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Abstract 
This study investigated whether 72 patients with pediatric-onset multiple sclerosis (MS) 
differed from 94 healthy controls on accuracy and response time on tests of episodic memory 
and identification of emotional expression using the Penn Computerized Neurocognitive Battery. 
We then tested the potential association between performance on episodic memory and emotion 
identification tests collapsing across the patient and control groups. Finally, we aimed to 
elucidate how neuropathology of the hippocampus, amygdala, and thalamus (using structural 
MRI), may impact episodic memory and emotion identification abilities. Results suggest that 
patients with pediatric-onset MS have difficulty with aspects of both episodic memory and 
emotion identification. Response time on all episodic memory tasks was positively associated 
with response time on the emotion tasks. Although patients demonstrated significantly smaller 
total and regional brain volumes, only thalamic volume appeared to relate to cognitive 
performance (i.e., response time on the Emotion Recognition test). Implications of emotion 
identification difficulties are discussed.
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1.0 Introduction and Background 
1.1 Overview of Multiple Sclerosis 
1.1.1 Diagnosis and Causes 
 Multiple Sclerosis (MS) is a chronic, inflammatory demyelinating disease of the central 
nervous system (CNS) in which the immune system attacks myelin, the protective covering of 
nerve cells. This results in impaired neuronal transmission. MS is thought to be the result of an 
interaction between genetic and environmental factors although the cause is still not clear (Love, 
2006). Some studies suggest that viruses, such as Epstein-Barr, may also play a role in the 
development of the disease (Wagner, Munger & Ascherio, 2004).  
 Patients experience different patterns of diffuse and focal lesions in both grey and white 
matter. Disease presentation is very heterogeneous as clinical symptoms may manifest depending 
on the location of neural damage (Love, 2006). Symptoms can include: sensory and physical 
impairment (e.g., visual and muscular disturbances including weakness, balance and pain), 
emotional changes (e.g., low mood), fatigue, and cognitive decline across several domains 
including memory (Compston & Coles, 2008; Amato, et al., 2016; Ekmekci, 2017; Parrish & 
Fields, 2019).  
 Across all countries, Canada reports one of the highest rates of MS, with approximately 
one in 385 individuals living with the disease (Multiple Sclerosis Society of Canada, 2017). MS 
also disproportionately affects females with a female to male ratio of approximately 3:1 (Ghezzi 
et al., 2017). There are marked differences in how the disease presents in males and females. 
Females typically have a slightly earlier disease onset, lower prevalence of primary progressive 
disease course, and slower progression of disability, in relation to males (Harbo, Gold & Tintoré, 
2013). The most common course of MS presents as relapsing-remitting (RRMS) (i.e., 
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neurological attack is followed by a relapse) versus primary progressive (i.e., consistent 
deterioration of neurologic function with no defined relapses) and secondary progressive (i.e., 
initially presenting as acute relapses and remissions, followed by a progressive course) (Multiple 
Sclerosis Society of Canada, 2017). The RRMS course is particularly prevalent in the pediatric-
onset type, accounting for approximately 93 to 100 percent of diagnoses (Yeh et al., 2009; Boiko 
et al., 2002; Ghezzi et al., 2002; Parrish & Fields, 2019; Waldman et al., 2014).  
1.2 Pediatric-Onset Multiple Sclerosis  
 Although MS is typically diagnosed in adulthood between the ages of 20 to 40 years, it 
can also occur in childhood and adolescence. Patients with pediatric-onset MS represent three to 
10 percent of all MS cases (Boiko et al., 2002; Yeh et al., 2009; Banwell et al., 2007; Waldman 
et al., 2014; Ghezzi et al., 2017). Although there are similarities in how the disease presents in 
adulthood and adolescence, in young children with MS, disease onset is typically marked by a 
higher frequency of symptoms indicative of cerebellar or brainstem involvement (Ghezzi et al., 
2017). Additionally, children and adolescents with MS have more pronounced inflammation and 
experience a greater number of relapses, particularly near disease onset, relative to adults with 
MS. It also takes longer to develop disability in this population compared to adults with MS 
despite more disease activity (i.e., high relapse rate) in pediatric patients (Suppiej & Cainelli, 
2014; Ghezzi et al., 2017).  
1.2.1 Multiple Sclerosis and the Developing Brain 
 The impact on brain development and consequences for brain function must be 
considered with earlier disease onset. Disease pathology (i.e., neuronal and axonal loss) develops 
during CNS myelinogenesis in pediatric-onset MS (Banwell & Anderson, 2005; Amato et al., 
2016). Disease pathology may also interrupt the development of cortical and subcortical 
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structures resulting in a failure to achieve age-expected brain volume (Aubert-Broche, et al., 
2014). The combination of having the disease before complete formation of white matter 
pathways and significant brain pathology including regional grey matter atrophy, may explain 
the unique cognitive and psychosocial difficulties patients with pediatric-onset MS experience 
(Ghezzi et al., 2017; Till et al., 2011).  
1.3 Cognitive Impairment in Pediatric-Onset Multiple Sclerosis 
 Cognitive impairment is identified in approximately 30 percent of pediatric-onset MS 
diagnoses and is typically observed before pronounced physical disability (Amato et al., 2008; 
Amato et al., 2010; Julian et al., 2013; Banwell & Anderson, 2005; Ghezzi et al., 2017). Working 
memory, attention, executive functions and information-processing speed are often 
compromised, and deficits may appear early in the disease course (Till et al., 2011). These 
processes are largely governed by the frontal lobes. The frontal lobes are the final brain region to 
undergo myelination which may explain deficits in these cognitive domains in patients with early 
disease onset (MacAllister et al., 2013; Till et al., 2011). Studies have demonstrated that younger 
age at disease onset and declining global and regional brain volume appear to impact the severity 
of cognitive deficits (Till et al., 2011; Banwell & Anderson, 2005; Amato et al., 2008; 
MacAllister et al., 2005; Amato, et al., 2016; Ekmekci, 2017; Parrish & Fields, 2019). 
Additionally, greater impairment over time is often noted when cognitive performance is studied 
longitudinally in patients with pediatric-onset MS (Amato et al., 2010).  
1.3.1 Memory 
An American study of 37 pediatric-onset MS patients (MacAllister et al., 2005) reported 
impairment (defined as performance <1.5 standard deviations (SD) below normative data) in 
immediate and delayed recall of visual information among 8.1% and 11% of patients, 
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respectively. Impairment in delayed recall (but not immediate recall) of verbal information was 
slightly more common, affecting about 19% of the sample. Expanded Disability Status Scale 
(EDSS; Kurtzke, 1983) score, a measure of physical disability, was the strongest predictor of 
memory impairment in this study, despite the sample not being especially physically impaired 
overall (EDSS ranging from zero to four) (MacAllister et al., 2007).  
Similar findings were reported by researchers of an Italian multicentre study which 
included 63 pediatric MS patients and 57 matched healthy controls (Amato et al., 2008). Again, 
greater verbal versus visual long-term memory deficits were found for pediatric-onset MS 
patients. Specifically, long-term recall was impaired among 39% of the sample for verbal 
information relative to 18% of the sample for visuospatial information. Immediate recall was 
impaired among 56% of the sample for verbal information. Similarly, immediate recall was 
impaired among 53% of the sample for visual information. In a later longitudinal study (Amato 
et al., 2010), declines in verbal memory were also found at two-year follow-up.  
Conversely, in a Canadian study of 32 pediatric MS patients and 26 age- and sex-
matched controls (Fuentes et al., 2012), groups performed similarly on verbal and nonverbal 
memory tasks when intellectual ability was held constant, though memory impairment was 
identified in approximately 20 percent of patients (similar to the rates reported in the American 
study). Memory was evaluated in this study using the Word Selective Reminding, Memory for 
Stories, Abstract Verbal Memory, and Face Memory tests from the Test of Memory and 
Learning, Second Edition (TOMAL-2; Reynolds & Voress, 2007). This study also investigated 
the association between regional brain volume and memory deficits in pediatric MS patients. 
Patients with MS showed reduced volume in the total brain, amygdala, and thalamus, but not the 
hippocampus, relative to controls. Total brain volume as well as regional brain volume of the 
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hippocampus, amygdala, and thalamus, correlated with memory performance in patients, but not 
controls. This brain-behaviour association has been observed in some (e.g., Benedict et al., 
2009), but not all studies in adults with MS (e.g., Rocca et al., 2016).  
A longitudinal Canadian study of 28 pediatric MS patients and 26 age-matched controls 
(Till et al., 2013) examined change in cognitive functioning within a 13- to 16-month interval. 
Again, the aforementioned subtests from the TOMAL-2 (Reynolds & Voress, 2007) were used to 
assess memory at both time points. A decline in visual memory performance was noted for three 
of 28 patients using the Reliable Change Index, although significant decline at the group level 
was not found on any measure for either group. Notably, patients did not show the same 
trajectory of memory development as controls over time, suggesting that the development of 
memory may be negatively impacted in patients with pediatric-onset MS. 
In summary, the majority of studies within pediatric-onset MS document memory 
impairment occurring in approximately one-fifth or fewer of pediatric MS patients, with the 
exception of one study (Amato et al., 2008) where memory impairment was found in roughly 
half of the sample for both visual and verbal information.  
1.3.2 Social Cognition 
 A recent focus in neuropsychological research within MS is social cognition. Social 
cognition is an umbrella term including theory of mind (ToM) and emotion recognition. 
Researchers have shown that infants are able to respond to happiness (e.g., the infant smiles in 
response to the presentation of a happy face) and sadness (e.g., the infant cries at the presentation 
of an angry face) at just a few months of age (Nelson, 1987). By the age of six, most typically 
developing children are able to discriminate several facial emotional expressions with a 
relatively high degree of accuracy (Lawrence, Campbell & Skuse, 2015; Herba & Phillips, 
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2004). Through development, happiness is generally recognized most accurately first, followed 
by negatively valanced emotions (e.g., sad, angry). Accuracy in identifying surprise and fear 
generally follow (Herba & Phillips, 2004). For the majority of children, emotions such as 
embarrassment, guilt, and pride are well recognized around age seven (Vetter et al., 2013). Sex 
differences also exist, whereby during childhood and adolescence females are significantly more 
accurate at recognizing facial emotional expressions overall, relative to males. There is a dearth 
of knowledge regarding the development of social cognitive abilities in adolescence. It has been 
suggested that emotion recognition and more complex aspects of social cognition show 
protracted development that extends into adulthood (Vetter et al., 2013). This may be due to 
ongoing development of brain networks that are responsible for these functions which continue 
to develop across adolescence and into early adulthood (Kilford et al., 2016). Social cognition 
may be impacted in MS, although findings are mixed (as described below).  
 A study by Pinto and colleagues (2012) examined the performance of adult patients with 
MS and healthy controls using the Emotion Recognition Test. In this task, after three seconds of 
examining a face on the computer, participants are given unlimited time to label faces as 
depicting either: anger, disgust, fear, happiness, sadness, surprise, or no expression. Performance 
of patients did not differ significantly from controls on the number of correct responses. 
However, deficits may not have been detected as these patients were in the early stages of MS 
(the mean time since clinical diagnosis was nine years). Worsening of cognitive abilities 
including challenges with recognizing facial expressions is expected with longer disease 
duration. 
 A recent meta-analysis by Cotter and colleagues (2016) included 13 studies of facial 
emotion recognition with adult MS patients and healthy controls matched for age, sex, years of 
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education, and IQ. In each study, participants were asked to label or discriminate between 
images of faces depicting different emotions (i.e., anger, disgust, fear, happiness, surprise, and 
sadness). Patients demonstrated poorer accuracy for all emotions tested relative to controls. 
However, statistically significant findings were only apparent for anger, sadness and fear; groups 
did not differ on happiness, surprise, or disgust (Cotter et al., 2016; Henry et al., 2017). Further, 
older patients with MS, irrespective of disease duration, were most impaired in identifying all 
emotions (Cotter et al., 2016).  
 ToM is another facet of social cognition that has been reported to be disturbed in 
pediatric-onset MS (Charvet et al., 2014). ToM is defined as the ability to infer one’s own mental 
states as well as the mental states of others (Henry et al., 2017). In a 2014 study by Charvet and 
colleagues, 28 pediatric MS patients and 32 healthy controls were administered the Reading the 
Mind in the Eyes Test (Baron-Cohen et al., 2001), Faux-Pas Test (Brüne & Brüne-Cohrs, 2006) , 
and First- and Second-Order False Beliefs (Perner & Wimmer, 1985) as measures of ToM. 
Overall, patients performed more poorly on all three tasks relative to controls. Taken together, 
there is a need for more studies to examine social cognitive outcomes in pediatric-onset MS. 
1.4 Grey Matter Neuropathology in Pediatric-Onset MS 
Studies have started to look beyond white matter in pediatric-onset MS based on findings 
in the adult MS literature. Researchers have discovered that the neuropathology in children with 
the disease also involves grey matter. Furthermore, the thalamus has been identified as a 
structure that is particularly vulnerable to pediatric-onset MS (Mesaros, 2008; Till et al., 2011; 
Kerbrat et al., 2012; Aubert-Broche et al., 2014). The consequences of thalamic damage include 
cognitive challenges, namely impairment in information processing, attention, memory, and 
auditory and visual integration (Till et al., 2011). The thalamus is also a highly connected 
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structure with projections to the hippocampus, making it a useful region of comparison when 
evaluating the pathology to other deep grey matter structures and consequences of this pathology 
for cognition.  
1.4.1 The Limbic System  
 The limbic system consists of several subcortical structures including the hippocampus 
and amygdala. Together, these structures form a complex network that is responsible for 
controlling and processing memory and emotions (Phelps, 2004; Rajmohan & Mohandas, 2007). 
Brain regions that comprise the limbic system may be compromised by MS, although findings 
are mixed as described below. 
1.4.2 The Hippocampus  
 The hippocampus is intricately involved in both spatial navigation and episodic memory 
(Wixted et al., 2018; Burgess et al., 2002). This structure undergoes progressive neuronal 
enlargement throughout childhood into adulthood. In typically developing individuals, 
myelination in the hippocampus increases in childhood until adolescence (Arnold & 
Trojanowski, 1996).   
1.4.3 The Amygdala 
 The amygdala is a central component of the limbic system that facilitates threat response 
and regulates memory and identification of facial emotional expressions (Krause, 2009). The 
response of the amygdala to emotions appears to be lateralized such that surprise and negative 
emotions like anger and sadness activate the right amygdala whereas fear activates the amygdala 
bilaterally. This laterality has also been demonstrated in research with individuals with MS 
(Henry et al., 2017; Cristinzio, Sander & Vuilleumier, 2007). Further, specific impairment in 
recognizing fear has been noted with amygdala lesions (Henry et al., 2017; Adolphs, 2002).  
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Structurally, the amygdala is said to reach adult volume in females by four years of age with 
development continuing until approximately age six in males (Tottenham & Sheridan, 2009; 
Giedd et al., 1996; Gilmore et al., 2012). Some studies also suggest that the left amygdala 
develops more rapidly relative to the right amygdala.  
1.4.4 The Hippocampus and Amygdala in Pediatric-Onset MS 
One study in pediatric-onset MS which included structural MRI and analysis of limbic 
structures found that normalized amygdala volume, but not hippocampal volume, differed 
significantly between patients and controls (Fuentes et al., 2012). In contrast, a study by Rocca 
and colleagues (2016) assessing hippocampal volume (but not amygdala) documented global and 
regional hippocampal volume loss in pediatric-onset MS patients. Amygdala pathology has been 
suggested to have deleterious effects on retention of learned visual and verbal information in 
pediatric-onset MS (Batista et al., 2017; Fuentes et al., 2012). It is also considered the strongest 
predictor of impairment in decoding the mental states of others (Batista et al., 2017). However, 
the impact of hippocampal and amygdala volume loss on identification of emotional expression 
in pediatric-onset MS has not been examined to our knowledge.  
2.0 Rationale 
 
 To date, no studies to our knowledge have examined the relationship between memory 
impairment and facial emotion identification in pediatric-onset MS. The association is important 
to clarify as navigating day-to-day interactions demand processing social cues in real-time while 
simultaneously relying on memories for past experiences that help to guide behaviour (Barnier et 
al., 2008; Spreng & Mar, 2012). As such, difficulties with memory and identifying others’ 
emotional expressions, may have functional consequences in the real world which can influence 
quality of life among MS patients. This can be particularly concerning in childhood and 
10 
     
   
   
   
 
adolescence, as these are developmental periods when peer relationships are salient and 
professional and romantic connections may be evolving (Scherf et al., 2013).  
Evidence from neuroimaging studies in MS suggest that abnormalities in brain structure 
and function may underlie cognitive and social processes. Further, several studies call for future 
research to examine the association between cognitive impairment, factors that contribute to 
social cognitive dysfunction, and neurologic changes that may predict difficulties in these areas 
(Cotter et al., 2016). 
Another gap in the pediatric-onset MS literature is the role of reduced processing speed, 
which is another common symptom of the disease, in contributing to impairments in memory 
function and social cognition. For example, if patients show reduced memory performance, it is 
important to probe whether the reduced performance is simply a manifestation of a general 
slowing of cognitive processing or whether performance is less accurate independent of speed. 
The methodology employed in the current research study has the potential to elucidate the role of 
information processing speed in specific cognitive deficits (i.e., episodic memory and 
identification of emotional expression) observed in pediatric-onset MS. 
3.0 Research Questions and Hypotheses 
 The overall objective of this study was to investigate the interrelationship between 
episodic memory, identification of emotional expression, and brain structures affiliated with 
these functions, in patients with pediatric-onset MS and healthy controls. The following specific 
aims were examined: 
Aim 1: To assess whether there is an association between episodic memory and identification of 
emotional expression.  
Hypothesis 1: Episodic memory will be positively associated with the ability to identify 
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emotional expressions collapsing across the patient and healthy control groups.  
Aim 2: To examine whether patients with pediatric-onset MS differ from healthy controls on 
episodic memory and identification of emotional expression tasks.  
Hypothesis 2: Patients will demonstrate poorer performance on measures of episodic memory 
and identification of emotional expression relative to healthy controls.   
Aim 3a: To assess whether patients with pediatric-onset MS have smaller hippocampal, 
amygdala, and thalamic volume relative to healthy controls. 
Hypothesis 3a: Regional brain volumes (hippocampal, amygdala, and thalamic volume) will be 
smaller among patients relative to healthy controls, with the thalamus showing the greatest 
difference between groups. 
Aim 3b: To determine whether total hippocampal, amygdala, and thalamic volume are 
independently associated with memory performance and identification of emotional expression. 
Hypothesis 3b: Given the role of the hippocampus and amygdala in processing emotion and 
regulating memory as well as the well-documented vulnerability of the thalamus to MS 
pathology (and its interconnections with limbic structures and the frontal lobe), smaller total 
hippocampal, amygdala, and thalamic volume will be independently associated with worse 
memory scores and poorer identification of emotional expression. 
4.0 Method 
4.1 Participants 
Baseline neurocognitive and neuroimaging data from the ongoing longitudinal Canadian 
Pediatric Demyelinating Study (CPDDS) collected between December 2015 and June 2019 were 
used. The CPDDS is a multi-site, longitudinal initiative across Canada as well as the Children’s 
12 
     
   
   
   
 
Hospital of Philadelphia (CHOP). Nine of the 15 participating sites had neurocognitive data 
available (Table 1). All participants had to be able to complete the test in English.  
Ninety-three patients with pediatric-onset MS were enrolled by the sites offering 
neurocognitive testing and neurocognitive data were obtained for 73 of these patients. Patients 
with established MS were recruited from previous phases of the national project via a letter of 
invitation which was either provided at their routine visit or by mail. Patients with incident MS 
were recruited consecutively from MS clinics at the Hospital for Sick Children (SickKids) and 
CHOP, as well as the University of Western Ontario using advertising (i.e., flyers, letters to 
residents and staff physicians, and web advertisement). Patients were between the ages of eight 
and 27 at the time of the assessment. Pediatric-onset MS patients were all confirmed to have 
their first attack before age 19 and have met the revised McDonald 2010 diagnostic criteria for 
relapsing-remitting MS (Polman et al., 2011). 
In addition, two sites enrolled 139 healthy controls (HCs; individuals in approximately 
the same age range as the patient group without MS). Recruitment of HCs took place at SickKids 
and CHOP using the same methods of advertisement used to recruit patients. HCs with a history 
of demyelinating syndrome were ineligible for the study. Forty-four HCs declined participation 
in the cognitive component of the study for unknown reasons. Of the HCs who completed the 
PCNB, one was excluded for expressing familiarity with the assessment battery. The final 
sample included 72 patients and 94 HCs (Figure 1).  
A subset of MRIs was analyzed as data collection was still ongoing at the time of the data 
pull. Regarding the MRI data that were available for processing, three of 51 patients were 
excluded from analyses despite adherence to the standardized scanning protocol and scans that 
passed quality control. This is because COMBAT (a method for estimating and controlling for 
13 
     
   
   
   
 
differences between scanners), cannot account for scanner-related variability at a given site when 
there are limited entries (i.e., less than two or three scans). Consequently, COMBAT rejects the 
scans from processing. One HC and one patient were excluded because accurate segmentations 
could not be obtained. Two HCs were excluded due to the presence of abnormalities on MRI. 
Two patients declined a research MRI due to claustrophobia or another unspecified reason. 
Finally, one patient could not be scanned as there was no scanner on-site (Supplemental Table 
2). Fifty-one patients (from a total of 72) and 61 HCs (of 94) had useable MRI data. Due to the 
scaling factor that was applied to the scans, participants were only included in MRI analyses if 
they were over 15 years of age at the time of their scan. This resulted in a final sample of 46 MS 
patients and 42 HCs with useable MRI data for the present study.  
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Figure 1. Study Enrollment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total participants recruited 
for Phase 3 of the CPDDS 
(December 2015 - June 2019)
(n  =  232)
MS patients recruited for 
Phase 3 of the CPDDS
(n = 93)
MS patients who underwent 
neurocognitive testing
(n = 73) 
MS patients excluded from analyses
Disability preventing completion or 
impairing neurocognitive performance 
(n = 1)
Age at MRI <15 Years (n = 5)
Total MS patients included in 
the present study
PCNB: (n = 72)
MRI: (n = 46)
MS patients who  did not 
undergo neurocognitive 
testing  (n = 20)
(declined for unknown reasons: 
n = 17; francophone: n = 3)
HCs recruited for Phase 3 of 
the CPDDS
(n = 139)
HCs who underwent 
neurocognitive testing 
(n = 95)
HCs excluded from the 
present study
Familiarity with the assessment 
battery (n = 1)
Age at MRI <15 Years (n = 19)
Total HCs included in the 
present study
PCNB: (n = 94)
MRI: (n = 42)
HCs who declined 
neurocognitive testing
Unknown reasons
(n = 44) 
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Table 1 
Sites with Available Neurocognitive Assessment Data  
 
Site MS Patients Assessed  
 
N 
HCs Assessed  
 
N 
Alberta Children's Hospital  1 - 
 
Children's Hospital at London Health 
Sciences Centre 
 
4 
 
- 
 
Children's Hospital of Philadelphia 
 
19 
 
28 
 
Hospital for Sick Children  
 
39 
 
67 
 
Janeway Children's Health and 
Rehabilitation Centre 
 
1 
 
- 
 
Montreal Children's Hospital  
 
5 
 
- 
 
The Children's Hospital of Manitoba 
 
2 
 
- 
 
Trillium Health Partners 
 
1 
 
- 
 
McMaster Children’s Hospital 
 
1 
 
- 
 
Total 
 
73 
 
95 
Note. One HC from the Hospital for Sick Children as well as the patient from McMaster 
Children’s Hospital were excluded from analyses.  
 
 
4.2 Ethical Considerations 
This research received ethics review and approval by the Human Participants Review 
Committee at York University as well as the Research Ethics Board (REB) at SickKids and all 
participating institutions involved in the CPDDS. Further, the research conforms to the standards 
of the Tri-Council Research Ethics guidelines. Research participants were fully informed about 
the research protocol and were asked to give their consent to participate. Participants age 16 
years and older provided written informed consent. Participants under 16 years of age provided 
assent and their parents/legal guardians provided written informed consent. Participants were 
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guaranteed that all identifying information would remain confidential and would only be used for 
the intended research purpose. Participant numbers were assigned, and confidentiality was 
maintained through the study.  
4.3 Measures 
4.3.1 Clinical-Demographic Information 
Core demographics, developmental milestones, education and occupation, and relevant 
personal and familial medical histories were recorded using standardized case report forms. 
Study site neurologists documented neurological findings, leading to determination of an 
approximated Expanded Disability Status Scale (EDSS) score.  
Symptoms of depression and anxiety in participants under 16 years of age were measured 
using the Paediatric Index of Emotional Distress (PI-ED; O'Connor et al., 2016). Participants age 
16 and over completed the Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 
1983). Both are 14-item questionnaires that generate an emotional distress score, based on a 
combined depression and anxiety score. A score greater than 20 on both measures is indicative of 
clinically significant emotional distress (O'Connor et al., 2016). Fatigue was measured using the 
PedsQL Multidimensional Fatigue Scale (Varni et al., 2002), with higher scores reflecting fewer 
problems. 
4.3.2 Cognitive Evaluation  
Participants completed the children's version of the Penn Computerized Neurocognitive 
Battery (PCNB) which takes approximately one hour to complete. The PCNB consists of 14 tests 
(Table 2) which assess: executive function (i.e., abstraction and flexibility, working memory, and 
attention), episodic memory (i.e., face, object, and word memory), complex cognition (i.e., 
language, nonverbal, and spatial reasoning), social cognition (i.e., emotion recognition and 
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emotion and age differentiation), and sensorimotor function. The order of presentation of these 
tests is consistent between participants to maintain engagement and prevent fatigue (Gur et al., 
2012) (Supplemental Table 1). Breaks are offered approximately every 15 minutes. All assessors 
completed a standard training protocol for administration of the PCNB.  
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Table 2 
Penn Neurocognitive Battery Subtests by Domain  
 
Domain Subtests Neurobehavioural function Brief Description 
Complex 
Cognition 
Penn Verbal Reasoning Test for 
Children 
verbal reasoning select from a list the word that best completes the verbal 
analogy 
Penn Matrix Analysis Test nonverbal reasoning choose the geometric piece that best completes the pattern 
Variable Penn Line Orientation 
Test 
spatial ability, visual 
discrimination 
rotate a line until it is parallel to a fixed line of a different 
length and orientation, using as few clicks as possible 
Executive 
Function 
Letter N-Back working memory, shifting one letter shown on screen at a time; press according to three 
rules, across three different conditions: (1) press for X, (2) 
press when the current letter is the same as the previous 
letter, (3) press when the current letter is the same as the 
letter that came before the previous letter 
respond when the appropriate letter is displayed amongst a 
series of letters 
Penn Continuous Performance 
Test 
sustained attention press for a letter/number; do not press for distractor items  
Penn Conditional Exclusion Test cognitive flexibility, rule 
learning, working memory 
identify which object of four does not belong based on one of 
three sorting principles; sorting principles switch after 10 
consecutive objects selected correctly  
Go-No-Go Task inhibitory control, sustained 
attention 
press for target letter in upper half of screen; do not press for 
nontarget letter or for letters in lower half of screen  
Sensorimotor Motor Praxis Test  motor planning and 
coordination 
quickly manipulate a computer mouse to click on a target 
that moves and changes size  
Penn Computerized Finger-
Tapping Test 
fine motor speed tap the spacebar using only the index finger as many times as 
possible within 10 000ms 
Social Cognition Age Differentiation Task age differentiation, visual 
discrimination 
identify which of two faces is older. Control condition task 
for current study. 
Penn Emotion Recognition Test 
for Children  
emotion identification identify the emotion shown on a given face from a list of 
emotions 
Measured Emotion 
Differentiation Task 
emotion differentiation identify which of two faces is showing an emotion to a 
greater degree 
Episodic Memory Penn Face Memory Test face recognition memory identify which faces have been seen previously  
Penn Word Memory Test for 
Children 
verbal recognition memory identify which words have been seen previously 
Visual Object Learning Test spatial recognition memory identify which figures have been seen previously  
Note. Subtests in bold are the primary outcomes used in the current study. 
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Each test on the PCNB provides a measure of both accuracy (i.e., number of correct 
responses) and response time (or efficiency of responding), with the exception of sensorimotor 
tests specifically designed for measuring motor speed. The PCNB has high sensitivity for 
detecting cognitive impairment in youth with different neuropsychiatric and medical conditions 
(Gur et al., 2014; Merikangas et al., 2017; Thomas et al., 2013; Ibrahim et al., 2016) and has 
been used to probe well-established brain systems with functional neuroimaging (Roalf et al., 
2014). Pediatric and adult versions have been developed with acceptable construct validity and 
psychometric properties (Gur et al., 2001; Roalf et al., 2014; Gur et al., 2010).  
The episodic memory and social cognition domains are the focus of the present study. 
Raw scores for each measure of accuracy and response time were standardized into Z-scores 
based on the means and standard deviations of the HC group. This approach was adopted in lieu 
of using the available PCNB norms as our cohort was not well matched with the established 
PCNB normative group in terms of demographics (namely parental education, a proxy for 
socioeconomic status). Consequently, using the available PCNB norms would have limited our 
ability to derive clinically meaningful Z-scores. Z-scores were calculated from three age bands 
(i.e., 8-13; 14-17; >18 years). Age bands were determined based on the developmental curves for 
the PCNB tasks (Gur et al., 2012) and with consideration of the number of participants in each 
group. Scores were transformed (i.e., multiplied by -1), where necessary (i.e., response time), 
such that higher Z-scores reflect better performance (i.e., more accurate, shorter response times). 
Composite scores were obtained by averaging Z-scores across the cognitive domains. Test 
performance was considered to be impaired if the Z-score fell 1.5 SD below the mean. 
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Penn Age Differentiation Test. This test serves as a control condition to compare against 
the emotion-related tasks. More specifically, the Age Differentiation Test is used in the present 
research to ensure participants have intact performance on a face processing task that is not 
contingent on emotion processing. Intact performance on this test would allow us to rule out 
difficulty in face processing that could potentially generalize to difficulties in facial emotional 
recognition. Across 36 trials with equal representation of male and female stimuli, this test 
measures the ability to perceive small visual differences. Pairs of faces are presented from the 
same target face that has been morphed to appear older or younger (Figure 2). Participants are 
asked to click the button labeled “This Face” below the face that is older or the central button, 
labeled “Both faces are the same age”, if both faces appear to be the same age (as is the case for 
four trials). Trials are presented in random order, and the test is a forced-choice task with no time 
limit per trial. Participants are given three practice trials before the test begins. 
 
Figure 2. Test Screenshot of the Age Differentiation Test from the PCNB. Copyright ©2006, 
2007 Trustees of the University of Pennsylvania 
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Penn Emotion Identification Test. Participants are presented with 40 faces one at a time 
and asked to determine what emotion the face is showing (Figure 3). There are five answer 
choices: Happy, Sad, Angry, Scared, and No Feeling. Participants respond to each trial by 
clicking with the mouse on the word describing the emotion each face depicts. There are four 
female faces for each emotion for a total of 20 female faces and four male faces for each emotion 
for a total of 20 male faces. The stimuli (coloured faces) are balanced for equality and intensity 
or emotion, age, gender and ethnicity (Kohler, Turner, Gur & Gur, 2004). The test is a forced-
choice task with no time limit per trial. Participants are given a practice trial before the test 
begins. 
 
Figure 3. Test Screenshot of the Penn Emotion Identification Test from the PCNB. 
 
Penn Emotion Differentiation Test. Across 36 trials with equal representation of male and 
female stimuli, this test measures the ability to detect emotional intensity (Figure 4). Pairs of 
emotional expressions from the same target face expressing the same emotion to varying degrees 
are presented. Participants are asked to click the button labeled “This Face” below the face that is 
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showing more emotion, or the central button, labeled “Equal”, if both faces are showing equal 
emotion (as is the case for 4 trials). Trials are presented in random order, and the test is a forced-
choice task with no time limit. Participants are given three practice trials before the test begins. 
 
Figure 4. Test Screenshot of the Measured Emotion Differentiation Test from the PCNB. 
Copyright ©2006, 2007 Trustees of the University of Pennsylvania 
 
 Penn Face Memory Test. Participants are presented with 20 black and white photographs 
of cropped faces (balanced for gender and age) one at a time for an encoding period of 5000 
milliseconds (ms) each and are asked to remember each face (Figure 5). Immediately upon 
completion of the presentation, participants are asked to identify, one at a time, which of 40 faces 
(20 test faces and 20 novel faces) they have seen before. Responses are made by using the 
computer mouse to select one option on a four-point scale: “definitely yes”, “probably yes”, 
“probably no” and “definitely no”. There are no practice trials for this test.
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Figure 5. Test Screenshot of the Penn Face Memory Test from the PCNB. 
 
 Penn Word Memory Test for Children. Participants are shown 20 words one at a time for 
an encoding period of 5000 ms each that they are asked to remember and later recognize (Figure 
6). Immediately upon completion of the presentation, participants are asked to identify, one at a 
time, which of 40 words (20 test words and 20 novel words) they have seen before by using the 
computer mouse to select one option on a four-point scale: “definitely yes”, “probably yes”, 
“probably no” and “definitely no”. All novel stimuli are matched for frequency, length, 
concreteness and imageability using Pavio’s norms (Pavio, Yuille & Madigan, 1968). There are 
no practice trials for this test.
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Figure 6. Test Screenshot of the Penn Word Memory Test from the PCNB. 
 
 Visual Object Learning Test. In this measure of visual object learning and memory, 
participants are shown 10 three-dimensional shapes one at a time for an encoding period of 5000 
ms each that they are asked to remember and later recognize (Figure 7). All stimuli have a 
geometric blue two-dimension shape within a three-dimensional figure which together comprise 
the 'whole figure' they are to remember. Immediately upon completion of the presentation, 
participants are asked to identify, one at a time which of 20 shapes (10 test shapes and 20 novel 
shapes) they have seen before by using the computer mouse to select one option on a four-point 
scale: “definitely yes”, “probably yes”, “probably no” and “definitely no”. There are no practice 
trials for this test.
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Figure 7. Test Screenshot of the Visual Object Learning Test from the PCNB. 
 
4.3.3 MRI Protocol: Image Acquisition 
A structural MRI scan was performed on a 3T scanner (different model at each site; 
Supplemental Table 2) according to a standardized research protocol. Four-fifths (80.36%) of 
participants were scanned on the same day as the neurocognitive assessment; the remaining one-
fifth (19.64%) of participants returned for scanning within an interval of one day to five months, 
eight days. The following list of sequences is outlined in the MRI Standard Operating Procedures 
from the Montreal Neurological Institute and were used to set up the scanners at each site. 
Notably, the parameters may vary slightly at each location depending on the manufacturer and 
model of the scanner: T1-weighted MPRAGE (TR 1810 ms, TE 3.51 ms, TI 1100 ms, flip angle 
9˚, 160 slices, voxel size 0.9 x 0.9 x 1 mm3); 3D FLASH without and with a magnetization 
transfer pulse to compute magnetization transfer ratio (MTR) (TR 33 ms, TE 3.86 ms, flip angle 
10˚, 192 slices, voxel size 1 x 1 x 1 mm3, GRAPPA factor 2; dual-angle B1 mapping pair (EPI-
SE, TR 4000 ms, TE 18 ms, voxel size 2 x 2 x 5 mm3, flip angles 60˚ and 120˚); 2D TSE proton 
density (PD)-weighted (TR 2200 ms, TE 10 ms, 60 slices, ETL 4, voxel size 1 x 1 x 3 mm3); 2D 
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TSE T2-weighted (TR 4500 ms, TE 84 ms, 60 slices, ETL 11, voxel size 1 x 1 x 3 mm3); 3D 
FLAIR (TR 5000 ms, TE 388 ms, TI 1800 ms, ETL 155, 208 slices, voxel size 1 x 1 x 1 mm3), 
DTI (TR 10300 ms, TE 94 ms, 30 diffusion-encoding directions, 50 slices, voxel size 2 x 2 x 2 
mm3, GRAPPA factor 2); T1-weighted pre/post gadolinium (3D FLASH TR 30 ms, TE 6.15 ms, 
flip angle 27˚, 60 slices, voxel size 1 x 1 x 3 mm3). Only T1-weighted images were analyzed for 
the purpose of the present study. Differences between scanners were controlled for using 
COMBAT (a computer algorithm that estimates scanner-related variability in the data).
5.0 Analyses 
5.1 Processing Cognitive Data 
During neurocognitive testing, the assessor noted behavioral and/or environmental 
observations pertinent to testing (e.g., presence of distractions, motivation towards the task, 
misunderstanding of instructions, and technical problems). Upon completion of the battery, data 
were sent to the CNB team at the University of Pennsylvania where quality control procedures 
were applied to each participant’s dataset. The data were plotted on a scatterplot to examine 
outliers (accuracy plotted on the Y axis and speed on the X axis). The data were then transferred 
via a data transfer agreement to SickKids and later to York University where the data underwent 
further quality control procedures (i.e., examination of assessor comments and removal of 
invalid participant data, checking for outliers, and Winsorizing). Secondary data analysis was 
then performed. 
5.2 MRI Processing 
Briefly, all images underwent quality control examination by neuroimaging experts at 
CHOP via the following preprocessing steps: evaluation for adequate signal-to-noise ratio, 
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ensuring freedom from significant motion or other artifact, and ensuring consistency of the 
sequence parameters.  
Total and lateralized brain volume of the hippocampus, amygdala, and thalamus for each 
hemisphere were calculated at CHOP by customizing existing routines (Iglesias et al., 2015; 
Saygin et al., 2017) available in FreeSurfer. Specifically, N4 was used for inhomogeneity 
correction as opposed to the default N3 and multi atlas skull stripping was used as a substitute 
for the default watershed algorithm. Lesions were in-painted using Lesion Segmentation 
Toolbox, to look like the normally appearing tissue around it. This step is important for ensuring 
that the segmentations are accurate.  
Brain tissue volume was then normalized for subject head size with the SIENAx tool in 
FSL (Smith et al., 2001; Smith e al., 2002; Smith et al., 2004). SIENAx extracts brain and skull 
images from the T1 MPRAGE data (Smith, 2002b). To normalize for head size, a volumetric 
scaling factor is obtained by affine-registering the brain image to MNI152 space (Jenkinson & 
Smith, 2001; Jenkinson et al., 2002). The skull image is used to determine the registration 
scaling. Specific tissue-type segmentation with partial volume estimation is then carried out 
(Zhang et al., 2001) and total volume of brain tissue is calculated (including separate volumes of 
grey matter, white matter, and ventricular cerebral spinal fluid (CSF). This process confirms that 
any differences in regional brain volume are not just due to differences in overall head size. 
Finally, the data were adjusted for scanner type using COMBAT. Data for participants at 
sites where there were only one or two entries, were excluded from MRI analyses as data could 
not be run through COMBAT.
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5.3 Statistical Analyses 
Data were analyzed using IBM SPSS Statistics version 24. To reduce the likelihood of a 
Type 1 error due to the multiple comparisons conducted, we adjusted the p-value to .01. Trends 
were also considered for group differences that did not meet this threshold for statistical 
significance. First, variables were plotted (histograms and boxplots) to assess normality and 
identify any outliers, across all outcomes. Outliers were Winsorized to three SD from the mean. 
The Shapiro-Wilk and Levene’s tests were used to identify possible violations of normality and 
homogeneity of variance within the data set.  
Descriptive statistics were examined for the clinical characteristics of the MS sample 
(i.e., fatigue, age at disease onset, disease duration, EDSS score, and use of disease-modifying 
therapies (DMT)). One-way analysis of variance (ANOVA) was used to compare the MS and 
HC groups on demographic variables (i.e., age, sex, level of education, and years of parental 
education).  
Two-tailed partial Pearson correlations (adjusted for accuracy or response time and/or sex 
where indicated) were used to examine relationships between each memory and emotional 
identification task, for MS patients, HCs, and collapsing across groups (Aim 1). Fisher’s Z-
Transformations were used to compare the strength of the differences in the correlation 
coefficients between the MS and HC groups. 
One-way analysis of covariance (ANCOVA) was used to compare groups on each of the 
episodic memory and social cognition tasks from the PCNB (Aim 2). Task-specific response 
time was included as a covariate for analyses of accuracy, and vice versa. Sex was included as a 
covariate when sex effects were present, as determined by comparison of male and female HC 
groups using independent samples t-tests. Effect sizes were determined using partial eta-squared 
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(2). Rates of impairment were compared between MS patients and HCs using a chi-squared (X2) 
test. One-way ANCOVAs were then used to probe whether there were differences between 
groups on the processing of specific emotions (e.g., anger, scared, sadness, happy, etc.) that were 
part of the Emotion Recognition and Emotion Differentiation tasks. Again, task-specific 
response time was included as a covariate for analyses of accuracy, and vice versa. 
In a sensitivity analysis, we excluded participants who failed the control task (as 
indicated by accuracy falling 1.5 SD below the mean on the Age Differentiation Test) and re-ran 
the analyses involving the emotion identification tasks. This approach allowed us to probe 
whether participants who struggled with face processing may have influenced the emotion 
identification findings. For the response time analyses, we also re-ran the between-group 
analyses controlling for sensorimotor speed. This approach allowed us to determine whether the 
differences in response time on the cognitive tasks were observed over-and-above expected 
differences on simple motor tasks. 
 One-way ANOVAs using regional brain volumes scaled with SIENAx were used to test 
whether patients with pediatric-onset MS have smaller total and lateralized hippocampal and 
amygdala volume relative to controls (Aim 3a). Thalamic volume was used to validate findings 
(i.e., to ensure that thalamic volume differed significantly between patients and HCs as 
demonstrated consistently in the literature). 
We ran two-tailed partial Pearson correlations (adjusted for accuracy or response time 
and/or sex where indicated) to examine the association between hippocampal, amygdala, 
thalamic, and total brain volume with cognitive outcomes for which MS patients differed 
significantly from HCs in terms of Z-score accuracy and Z-score response time (Aim 3b). 
Finally, multiple linear regressions predicting cognitive outcome were only conducted when near 
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significant associations were observed between a given task and regional brain volume to 
elucidate the variance in performance accounted for by a given brain structure. Statistical 
significance was established for regression analyses using a p-value of <.05 to capture the 
smaller effect sizes. 
6.0 Results 
6.1 Neurocognitive Outcomes  
6.1.1 Sample Characteristics 
In total, cognitive data were analyzed for 72 MS patients and 94 healthy controls. 
Demographic and disease-related characteristics of the sample are reported in Table 3. MS 
patients were, on average, older than controls at the time of the neurocognitive assessment (18.1 
versus 16.7 years) (p = .05); groups did not differ significantly with respect to sex, level of 
education, years of parental education, or emotional distress. However, they did differ 
significantly (all values ≤.01) with respect to both parent and participant rated levels of fatigue. 
MS patients were tested at variable intervals from disease onset, ranging from less than one 
month to 11 years (M = 4.0 years, SD = 3.9 years); 25 of 72 (34.72%) patients had a disease 
duration greater than five years. Age at MS onset ranged from 5.9 to 18.8 years (M = 14.5, SD = 
2.8), and 11 of 72 (15.3%) had their first attack prior to age 12 years. MS patients had a median 
EDSS score of 1.5 ranging from 0-6.5 and 56 of 72 (77.8%) patients were receiving disease-
modifying treatment at the time of the assessment.
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Table 3 
Demographic and Clinical Characteristics of the PCNB MS and HC Groups   
 
Characteristic MS (n = 72) 
M(SD) / N(%) 
HC (n = 94) 
M(SD) / N(%) 
 
p 
Age at testing (years, range) 18.1 (8-27) 16.7 (8-29) .05 
Sex (male/female, %) 18/54 (75%) 35/59 (62.8%) 1.00 
Participant education (years) 11.5 (3.3) 10.8 (4.3) .23 
Parental education    
Father's education (years) 12.5 (4.9) 13.2 (5.5) .39 
Mother's education (years) 13.8 (3.7) 13.8 (5.1) 1.00 
Emotional Distress (normal/high, %)† 67/7 (9.7) 76/3 (3.2) .13 
Fatigue    
     Parent†    
          General Fatigue 67.5 (85.6) 85.6 (15.6) <.001 
          Sleep Rest Fatigue 67.2 (24.3) 83.6 (17.2) <.001 
          Cognitive Fatigue 70.7 (25.7) 85.6 (16.5) <.001 
          Total 68.4 (22.2) 84.9 (14.6) <.001 
     Participant†    
          General Fatigue 66.9 (23.0) 79.3 (15.1) <.001 
          Sleep Rest Fatigue 60.3 (21.6) 68.4 (17.4) .01 
          Cognitive Fatigue 66.6 (25.5) 78.4 (17.0) .001 
          Total 64.5 (20.6) 75.4 (13.9) <.001 
EDSS (median, range) 1.5 (0-6.5) - - 
Age at disease onset (years)† 14.5 (2.8) - - 
DMT (N/Y, %) 16/56 (77.8) - - 
Disease Duration (months) 48.1 (46.9) - - 
Abbreviations: MS = multiple sclerosis; HC = healthy control; EDSS = Expanded Disability 
Status Scale; DMT = Disease Modifying Therapy 
†Emotional Distress data not available for two patients and 17 HCs. 
†Parent rated fatigue data not available for 11 patients and 25 HCs.  
†Participant rated fatigue data not available for 2 patients and 8 HCs. 
†Age at disease onset data not available for one patient. 
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6.1.2 Associations between Episodic Memory and Identification of Emotional Expression 
(Accuracy) 
 Table 4 shows the correlations between the subtests in the social cognition and episodic 
memory domains. Overall, accuracy of performance on Face Memory (controlling for reaction 
time) correlated moderately with Emotion Recognition (r = .28, p = .001) and Emotion 
Differentiation (r = .32, p <.001), collapsing across groups.  
Collapsing across groups, accuracy on Object Memory (controlling for reaction time) did 
not reach significance with accuracy on the Emotion Recognition (r = -.03, p = .73) but 
approached significance with the Emotion Differentiation subtest (r = .16, p = .04). Object 
Memory was significantly positively associated with Emotion Differentiation for patients (r = 
.31, p = .01) but not controls.  
Finally, accuracy on the Word Memory subtest (controlling for reaction time) 
demonstrated a significant positive association with accuracy on the Emotion Differentiation 
subtest collapsing across groups (r = .25, p = .001) but not Emotion Recognition.  
Correlations between Face and Object Memory with the social cognition tasks were 
slightly stronger among the MS group relative to controls, although the differences were not 
statistically significant when compared using Fisher’s Z-transformation. 
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Table 4 
Correlations (two-tailed) Between Z-score Accuracy on Episodic Memory and Social Cognition Subtests in Patients with MS and HCs 
 
 
Social Cognition Subtests 
Episodic Memory Subtests 
  
 
N 
 
Face Memorya 
 
 
 
N 
 
Object Memorya,b 
 
 
N 
 
Word Memorya 
 
 
 
 
N 
Emotion Recognitiona,b 164 
71 
93 
r = .28, p = .001*** 
r = .38, p = .001*** 
r = .26, p = .01* 
163 
72 
91 
 
 
 
r = -.03, p = .73 
r = .07, p = .59 
r = -.05, p = .67 
163 
70 
93 
r = -.01, p = .90 
r = -.05, p = .68 
r = .05, p = .62 
165 
72 
93 
Emotion Differentiationa 166 
72 
94 
r = .32, p <.001*** 
r = .35, p = .003*** 
r = .27, p = .009** 
163 
72 
91 
r = .16, p = .04* 
r = .31, p = .01* 
r = .04, p = .72 
163 
70 
93 
r = .25, p = .001*** 
r = .21, p = .08 
r = .25, p = .02* 
165 
72 
93 
All participants (166), MS patients (n = 72), Healthy Controls (n = 94) 
a Partial correlations controlling for response time 
b Partial correlations controlling for sex 
Note. Sample size differs across tests because data were missing or deemed invalid for some patients.  
* p <.05; ** p <.01; *** p <.005 
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6.1.3 Associations between Episodic Memory and Identification of Emotional Expression 
(Response Time) 
 Response time across all episodic memory and social cognition tasks (controlling for 
accuracy) were moderately to highly correlated collapsing across groups (r values ranging from 
.25 to .49; all p values ≤.001). As with the associations using the accuracy data, correlations were 
slightly stronger (though not statistically different) among the MS group relative to controls for 
all relationships except for two comparisons: Object Memory and Emotion Recognition (for 
which the strength of the correlation was similar between groups) and Word Memory and 
Emotion Differentiation (Table 5).  
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Table 5 
Correlations (two-tailed) Between Z-score Response Time on Episodic Memory and Social Cognition Subtests in Patients with MS 
and HCs 
 
 
Social Cognition Subtests 
Episodic Memory Subtests 
  
 
N 
 
Face Memorya 
 
 
 
N 
 
Object Memorya 
 
 
N 
 
Word Memorya 
 
 
 
 
N 
Emotion Recognitiona 164 
71 
93 
r = .43, p <.001*** 
r = .48, p <.001***  
r = .31, p = .003*** 
163 
72 
91 
 
 
 
r = .41, p <.001*** 
r = .41, p <.001*** 
r = .42, p <.001*** 
163 
70 
93 
r = .49, p <.001*** 
r = .59, p <.001*** 
r = .28, p = .007** 
165 
72 
93 
Emotion Differentiationa 166 
72 
94 
r = .36, p <.001***  
r = .40, p = .001***  
r = .31, p = .003*** 
163 
72 
91 
r = .35, p <.001*** 
r = .36, p = .003***  
r = .33, p = .001*** 
163 
70 
93 
r = .25, p = .001***  
r = .20, p = .10  
r = .28, p = .006** 
165 
72 
93 
All participants (n = 166), MS patients (n = 72), Healthy Controls (n = 94) 
a Partial correlations controlling for accuracy 
Note. Sample size differs across tests because data were missing or deemed invalid for some patients.  
* p <.05; ** p <.01; *** p <.005 
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6.1.4 Between Group Comparisons on the Social Cognition and Episodic Memory Outcomes 
on the PCNB 
Overall, the mean scores across all subtests examined and across both groups fell solidly 
within the average range. Accuracy and response time were compared separately for each group 
on each test (Tables 6 and 7). Overall, these two metrics were weakly correlated across all 
subtests (r values ranging from -.03 to .28 collapsing across groups, -.27 to .20 in the patient 
group, and -.07 to .26 among HCs) (Table 8). 
6.1.5. Between Group Comparisons on the Social Cognition and Episodic Memory Outcomes 
on the PCNB (Accuracy) 
Accuracy on the episodic memory and social cognition subtests is presented in Table 6 
and depicted visually in Figure 8. After controlling for response time and sex where indicated, 
MS patients demonstrated significantly poorer performance on the Word Memory subtest (p = 
.002, 2p = .06) and the episodic memory domain score (p <.001, 2p = .07) relative to HCs. 
Overall, patients were less accurate than HCs on five of six subtests (though statistical 
significance was only reached for Word Memory) and were more accurate on one subtest (i.e., 
Emotion Recognition). The proportion of participants showing impairment on the social 
cognition and episodic memory subtests did not differ significantly between groups.  
Accuracy on the Age Differentiation subtest was used as a control condition to ensure 
intact face processing. Results showed that six of 72 (8.3%) of MS patients and 7 of 94 (7.4%) of 
HCs were impaired on this subtest. In a sensitivity analysis, analyses for the emotion 
identification tasks were re-run after excluding all participants who were identified as impaired 
on accuracy for the Age Differentiation Test. Excluding these participants did not influence the 
results (Supplemental Table 3). Therefore, it was decided to retain these data points in 
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subsequent analyses as exclusion of these participants did not impact performance at the group 
level on the emotion tasks that were of primary interest.  
As demonstrated in previous research within MS, the amygdala has a differential ability 
to recognize (i.e., accuracy) and respond to (i.e., reaction time; efficiency of responding) specific 
emotions such as surprise and negative emotions (e.g., anger and sadness). Therefore, as an 
exploratory analysis, we then probed whether the patients with MS would show a 
disproportionate deficit in their ability to recognize and respond to faces depicting fear, anger, 
and sadness relative to faces with happy and neutral expressions. Notably, Z-scores for the happy 
expression were not computed due to lack of variation caused by a ceiling effect. Contrary to 
previous research within MS, the patient group did not show a disproportionate deficit in their 
ability to recognize faces depicting various emotions, relative to controls (Table 9). Consistent 
with the literature, MS patients appear to respond significantly slower than HCs to faces 
depicting anger and sadness relative to faces with fearful and neutral expressions (Table 10).   
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Table 6 
Comparison Between Patients with MS and HCs on Accuracy Z-scores and With Respect to the Proportion Showing Impairment on 
Episodic Memory and Social Cognition Subtests 
 
Domain 
 
 
Task 
 
 
MS group HC group Group difference 
Proportional 
analysis 
M(SE) 
Impaired % 
(n/N) 
M(SE) 
Impaired % 
(n/N) 
F p 
partial 
2 
X2 p 
Social 
Cognitiona,b 
 -0.01 (0.08)  0.01 (0.07)  .01 .91  <.001   
Age Differentiationa -0.06 (0.11) 8.3 (6/72) -0.01 (0.10) 7.4 (7/94) .09 .77 .001 0.04 1.00 
Emotion 
Recognitiona,b 
0.28 (0.12) 0 (0/71) -0.06 (0.09) 8.6 (8/93) 5.19 .02 .03 6.42 .01 
Emotion 
Differentiationa 
-0.25 (0.11) 5.6 (4/72) 0.02 (0.10) 5.3 (5/94) 3.17 .08 .02 0.004 1.00 
Episodic 
Memorya 
 -0.44 (0.09)  -0.02 (0.08)  12.64  <.001 .07   
Face Memorya -0.29 (0.12) 18.1 (13/72) -0.02 (0.11) 8.8 (8/91) 2.92 .10 .02 3.07 .10 
Object Memorya,b -0.23 (0.15) 18.6 (13/70) 0.04 (0.12) 8.6 (8/93) 1.94 .17 .01 3.54 .10 
Word Memorya -0.60 (0.13) 22.2 (16/72) -0.06 (0.12) 11.8 (11/93) 9.61 .002 .06 3.20 .09 
Abbreviations: MS = multiple sclerosis; HC = healthy control 
Note. p-values (ANCOVA) represent group differences after controlling for response timea and sexb (where indicated); Classification 
of impairment was based on a score falling 1.5 standard deviations below the mean; Sample size differs across tests because data were 
missing or deemed invalid for some patients.  
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Figure 8. Accuracy Z-score for MS and HC Groups on Episodic Memory and Social  
Cognition Subtests. 
Note. Error bars reflect ±1 standard error. 
 
 
6.1.6 Between Group Comparisons on the Social Cognition and Episodic Memory Outcomes 
on the PCNB (Response Time) 
 First, group differences on sensorimotor tasks (i.e., Motor Praxis (mouse control) and 
Finger Tapping (finger speed using the spacebar)) were examined as potential confounds. The 
sensorimotor tasks included in the PCNB are described briefly above (Table 2). Significant 
between group differences were observed on Finger Tapping (p = .009, 2p = .04), but not Motor 
Praxis.  
Response time Z-scores on the episodic memory and social cognition subtests are 
presented in Table 7a and depicted visually in Figure 9. After controlling for accuracy, on 
average the MS group was slower to respond on all tasks, although significant group differences 
were only apparent on Emotion Recognition (p = .009, 2p = .04). The proportion of patients 
meeting criteria for impairment was higher on all social cognition and episodic memory subtests 
among the MS patients, although none reached statistical significance. Of note, 12 of 72 (16.7%) 
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of MS patients were impaired on the Word Memory subtest as compared with only five of 93 in 
the HC group (X2 = 5.60, p = .02). Post-hoc analyses examining between group differences on 
response time were examined holding response time on the motor tasks (i.e., sensorimotor 
domain score) constant. The pattern of results remained the same (Table 7b) confirming that the 
deficits in response time on Emotion Recognition exist above and beyond motor slowness. 
Additionally, response time on the Word Memory test reached significance controlling for motor 
speed. 
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Table 7a 
Response Time Z-scores and Impairment on Episodic Memory, Social Cognition, and Sensorimotor Subtests 
 
Domain 
 
 
Task 
 
 
MS group HC group Group difference 
Proportional 
analysis 
  
M(SE) 
Impaired % 
(n/N) 
M(SE) 
Impaired % 
(n/N) 
F p partial 
2 
X2 p 
Social 
Cognitiona 
 
 -0.35 (0.11)  -0.001 (0.10)  5.86 .02 .04   
Age Differentiationa -0.37 (0.13) 16.7 (12/72) -0.01 (0.11) 8.5 (8/94) 4.54 .04 .03 2.56 .15 
Emotion 
Recognitiona 
-0.49 (0.14) 15.5 (11/71) 0.00 (0.12) 6.5 (6/93) 6.90 .009 .04 3.54 .07 
Emotion 
Differentiationa 
 
-0.20 (0.13) 12.5 (9/72) 0.02 (0.11) 7.4 (7/94) 1.63 .20 .01 1.20 .30 
Sensorimotor  -0.13 (0.07)  0.00 (0.06)  1.89 .17 .01   
 Motor Praxis 0.29 (1.15) 0 (0/72) 0.00 (0.99) 2.1 (2/94) 3.10 .08 .02 1.55 .51 
Finger Tappingb 
 
-0.39 (0.14) 
 
15.7 (11/70) 
 
0.06 (0.10) 
 
8.5 (8/94) 
 
6.96 
 
.009 
 
.04 
 
2.03 
 
.22 
 
Episodic 
Memorya 
 
 
-0.41 (0.11)  -0.07 (0.10)  4.97 .03 .03   
Face Memorya -0.38 (0.13) 16.7 (12/72) -0.02 (0.12) 7.7 (7/91) 4.27 .04 .03 3.14 .09 
Object Memorya -0.27 (0.13) 14.3 (10/70) -0.11 (0.11) 6.5 (6/93) 0.76 .38 .01 2.77 .12 
Word Memorya -0.46 (0.13) 16.7 (12/72) -0.05 (0.11) 5.4 (5/93) 5.47 .02 .03 5.60 .02 
Abbreviations: MS = multiple sclerosis; HC = healthy control 
Note. p-values (ANCOVA) represent group differences after controlling for accuracya and sexb (where indicated); Classification of 
impairment was based on a score falling 1.5 standard deviations below the mean; Sample size differs across tests because data were 
missing or deemed invalid for some patients.
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Figure 9. Response Time Z-score for MS and HC Groups on Episodic Memory, Social Cognition, and Sensorimotor Subtests. 
Note. Error bars reflect ±1 standard error. 
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Table 7b 
Response Time Z-scores and Impairment on Episodic Memory and Social Cognition Subtests controlling for Motor Speed 
 
Domain 
 
 
Task 
 
 
Group difference 
  F p partial 2 
Social Cognitiona,b 
 
 7.03 .009 .04 
Age Differentiationa,b 4.89 .03 .03 
Emotion Recognitiona,b 8.52 .004 .05 
Emotion Differentiationa,b 
 
1.89 .17 .01 
Episodic Memorya,b  
 
5.66 .02 .03 
Face Memorya,b 4.34 .04 .03 
Object Memorya,b 0.94 .33 .01 
Word Memorya,b 6.20 .01 .04 
Note. p-values (ANCOVA) represent group differences after controlling for accuracya and motor speed (i.e., sensorimotor domain 
score)b; Sample size differs across tests because data were missing or deemed invalid for some patients.
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Table 8 
Correlations (two-tailed) Between Z-score Accuracy and Response Time on Episodic Memory and Social Cognition Subtests in 
Patients with MS and HCs 
 
 
Accuracy 
 Response Time 
  
 
N 
Emotion 
Recognitionc 
Emotion 
Differentiationc 
Face Memoryc Object Memoryc Word Memoryc 
Emotion Recognitiona,b 164 
71 
93 
r = -.04, p = .61 
r = -.19, p = .11 
r = .13, p = .21 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Emotion Differentiationa 166 
72 
94 
- 
- 
- 
r = -.15, p = .05  
r = -.27, p = .02* 
r = -.07, p = .51 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Face Memorya 163 
72 
91 
- 
- 
- 
- 
- 
- 
r = .14, p = .09 
r = .17, p = .33 
r = .11, p = .32 
- 
- 
- 
- 
- 
- 
Object Memorya,b 163 
70 
93 
- 
- 
- 
- 
- 
- 
- 
- 
- 
r = -.03, p = .70 
r = -.05, p = .71 
r = -.04, p = .73 
- 
- 
- 
Word Memorya 165 
72 
93 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
r = .28, p <.001*** 
r = .20, p = .10 
r = .26, p = .01* 
All participants (n = 166), MS patients (n = 72), Healthy Controls (n = 94) 
a Partial correlations controlling for response time 
b Partial correlations controlling for sex 
c Partial correlations controlling for accuracy 
Note: Sample size differs across tests because data were missing or deemed invalid for some patients.  
* p <.05; ** p <.01; *** p <.005 
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Table 9 
Estimated Marginal Means (Standard Error) for Comparison of MS and HCs on Z-scores of Accuracy by Emotion 
 
Subtest Emotion 
 
MS 
 
M (SE) 
HC 
 
M (SE) 
 
 
F 
 
 
p 
 
 
 
partial 2 
Emotion 
Recognition 
      
 
 
 
Angrya 
 
0.08 (0.11) 
 
-0.03 (0.09) 
 
0.58 
 
.45 
 
.004 
  
Scareda,b 
 
0.15 (0.13) 
 
-0.05 (0.10) 
 
1.50 
 
.22 
 
.01 
  
Sada 
 
0.22 (0.10) 
 
-0.02 (0.09) 
 
2.88 
 
.09 
 
.02 
  
Happy† 
 
N/A 
 
N/A 
 
- 
 
- 
 
- 
  
No Expressiona 
 
0.23 (0.10) 
 
0.02 (0.08) 
 
2.73 
 
.10 
 
.02 
 
Emotion 
Differentiation 
      
 
 
 
Angrya 
 
-0.10 (0.12) 
 
0.01 (0.10) 
 
0.45 
 
.50 
 
.003 
  
Scareda 
 
-0.28 (0.11) 
 
0.01 (0.10) 
 
3.86 
 
.05 
 
.02 
  
Sada 
 
-0.24 (0.12) 
 
0.01 (0.10) 
 
2.62 
 
.11 
 
.02 
  
Happya,b 
 
-0.13 (0.12) 
 
-0.04 (0.10) 
 
0.33 
 
.56 
 
.002 
Abbreviations: MS = multiple sclerosis; HC = healthy control 
Note. p-values (ANCOVA) represent group differences after controlling for response timea and sexb (where indicated); Sample size 
differs across tests because data were missing or deemed invalid for some patients.   
†Norms for Emotion Recognition Happy could not be computed due to ceiling effect (i.e., lack of variation) 
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Table 10 
Estimated Marginal Means (Standard Error) for Comparison of MS and HCs on Z-scores of 
Response Time by Emotion 
 
Subtest Emotion MS 
 
M (SE) 
HC 
 
M (SE) 
 
 
F 
 
 
p 
 
 
 
partial 2 
Emotion 
Recognition 
      
  
Angrya 
 
-0.50 (0.13) 
 
0.00 (0.11) 
 
8.61 
 
.004 
 
.05 
  
Scareda 
 
-0.27 (0.13) 
 
0.01 (0.12) 
 
3.05 
 
.12 
 
.02 
  
Sada 
 
-0.38 (0.12) 
 
0.04 (0.10) 
 
7.52 
 
.007 
 
.05 
  
Happy† 
 
N/A 
 
N/A 
 
- 
 
- 
 
- 
  
No 
Expressiona 
 
-0.09 (0.12) 
 
0.03 (0.10) 
 
0.56 
 
.46 
 
.003 
 
Emotion 
Differentiation 
      
  
Angrya 
 
-0.15 (0.12) 
 
0.01 (0.11) 
 
0.95 
 
.33 
 
.01 
  
Scareda 
 
-0.26 (0.14) 
 
0.01 (0.12) 
 
3.31 
 
.13 
 
.01 
  
Sada 
 
-0.11 (0.11) 
 
0.04 (0.10) 
 
0.95 
 
.33 
 
.01 
  
Happya 
 
-0.04 (0.11) 
 
0.01 (0.10) 
 
0.11 
 
.74 
 
.001 
Abbreviations: MS = multiple sclerosis; HC = healthy control 
Note. p-values (ANCOVA) represent group differences after controlling for accuracya (where 
indicated); Sample size differs across tests because data were missing or deemed invalid for 
some patients.   
†Norms for Emotion Recognition Happy could not be computed due to ceiling effect (i.e., lack of 
variation) 
 
 
6.1.7 Clinical Predictors of Cognitive Outcomes 
 
There were no significant associations between clinical characteristics of the MS group 
and performance on tasks that was identified as being poorer in the MS group relative to HCs 
(i.e., Word Memory accuracy and Emotion Recognition response time).  
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6.2 Magnetic Resonance Imaging (MRI) Results 
6.2.1 Sample Characteristics 
In total, MRI data were analyzed for 46 of the 72 (63.9%) MS patients and 42 of the 94 
(44.7%) healthy controls (data for some participants were not yet available at the writing of this 
thesis). Participants were only included in MRI analyses if they were at least 15 years of age at 
the time of scan (this decision was made due to concerns about the brain normalization 
procedure (SIENAx) possibly being affected by smaller head size, which in turn could impact 
the brain volumetric outcomes in the current analyses). Demographic and disease-related 
characteristics of the sample are reported in Table 11. Patients included in the MRI subsample 
did not differ significantly from HCs in the subsample with respect to age, sex, level of 
education, years of parental education or emotional distress. MS patients were scanned at 
variable intervals from disease onset (mean = 4 years; SD = 4), with 18 of 46 (39.1%) having a 
disease duration greater than five years. Age at MS onset ranged from 5.9 to 17.9 years (M = 
14.99, SD = 2.39), and 6 of 46 (13.0%) had their first attack prior to age 12 years. MS patients 
had a median EDSS score of 1.5 (range = 0-6.5) and 35 of 46 (76.1%) patients were receiving 
disease-modifying treatment at the time of the assessment.  
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Table 11 
Demographic and Clinical Characteristics of MS and HCs ≥ 15 Years at Scan 
 
Characteristic MS (n = 46) 
M(SD) / N(%) 
HC (n = 42) 
M(SD) / N(%) 
 
p 
Age at scan (years, range) 
 
19.0 (15-27) 
 
19.8 (15-28) 
 
.32 
Sex (female, %) 
 
33 (71.7) 
 
31 (73.8) 
 
.83 
Participant education (years) 
 
12.1 (3.0) 
 
13.9 (3.0) 
 
.01 
Parental education  
   
Father's education (years)  
 
12.5 (5.0) 
 
14.3 (4.6) 
 
.10 
Mother's education (years)  
 
13.8 (3.0) 
 
14.5 (4.2) 
 
.39 
Emotional Distress† 
 
10.1 (7.1) 
 
9.15 
 
.52 
EDSS (median, range) 
 
1.50 (0-6.5) 
 
- 
 
- 
Age at disease onset (years) 
 
15.0 (2.4) 
 
- 
 
- 
DMT (N/Y, %) 
 
11/35 (76.1) 
 
- 
 
- 
Disease Duration (months) 
 
51.7 (47.1) 
 
- 
 
- 
Abbreviations: MS = multiple sclerosis; HC = healthy control; EDSS = Expanded Disability 
Status Scale; DMT = Disease Modifying Therapy 
†Emotional Distress data not available for 1 patient and 8 HCs. 
 
 
6.2.2 MRI Outcomes 
 MRI analysis, in line with our hypotheses, revealed that total regional brain volumes of 
the hippocampus, amygdala, and thalamus (all corrected for skull size using SIENAx) differed 
significantly between the two groups, with the MS group displaying reduced volumes compared 
to the HC group (Table 12; Figure 10). Normalized total brain volume was also significantly 
smaller among patients versus HCs. Normalized grey matter volume was significant at trend 
levels (p = .03) with the MS group having lower grey matter volumes than HCs. Additionally, 
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although normalized white matter volume did not differ significantly between groups, the means 
are in the anticipated direction with the MS group having slightly smaller volume. Brain regions 
in the left and right hippocampus (r = .85, p <.001), amygdala (r = .86, p <.001), and thalamus (r 
= .80, p <.01), were all highly correlated (collapsing across groups). Thus, total bilateral volumes 
were used in all analyses. 
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Table 12 
Structural MRI metrics (mm3) for MS and HCs ≥ 15 Years at Scan 
 
MRI metric MS (n = 46) 
M(SD) 
HC (n = 42) 
M(SD) 
 
F 
 
p 
 
partial 2 
Hippocampal volume      
 
Total 
 
9003.22 (838.05) 
 
9617.74 (741.51) 
 
13.17 
 
<.001 
 
.13 
 
Left 
 
4423.97 (445.85) 
 
4720.23 (352.65) 
 
11.80 
 
.001 
 
.12 
 
Right 
 
4579.25 (424.43) 
 
4897.51 (415.02) 
 
12.61 
 
.001 
 
.13 
 
Amygdala volume 
     
 
Total 
 
4510.33 (423.40) 
 
4728.22 (334.45) 
 
7.15 
 
.009 
 
.08 
 
Left 
 
2216.62 (224.27) 
 
2317.29 (167.07) 
 
5.39 
 
.02 
 
.06 
 
Right 
 
2291.72 (214.30) 
 
2411.94 (181.41) 
 
7.99 
 
.006 
 
.09 
 
Thalamic volume 
     
 
Total 
 
19524.84 (2256.68) 
 
21934.03 (1923.20) 
 
28.78 
 
<.001 
 
.25 
 
Left 
 
9961.09 (1157.29) 
 
11142.85 (1020.01) 
 
25.62 
 
<.001 
 
.23 
 
Right 
 
9563.76 (1224.08) 
 
10791.18 (984.71) 
 
26.54 
 
<.001 
 
.24 
 
Normalized Grey 
Matter volume 
 
844335.9 (52322.46) 
 
867553.5 (47863.01) 
 
4.68 
 
.03 
 
.05 
 
Normalized White 
Matter volume 
 
714744.31 (44557.13) 
 
730302.4 (40989.52) 
 
2.89 
 
.09 
 
.03 
 
Normalized Total 
Brain volume 
 
1559337 (61201.72) 
 
1596860 (68728.77) 
 
7.34 
 
.008 
 
.08 
Note. Brain volumes normalized with SIENAx scaling 
†MRI data not available for 21 MS patients and 33 HCs. 
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Figure 10. Regional Structural MRI Metrics (mm3) for MS and HC Groups. 
Note. Error bars reflect ±1 standard deviation. 
 
 
 
 
Figure 11. Normalized Grey Matter, White Matter, and Total Brain Volume MRI Metrics (mm3) 
for MS and HC Groups. 
Note. Error bars reflect ±1 standard deviation. 
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6.2.3 Clinical Predictors of Brain Volume  
Within the MS group, EDSS score was correlated with both total amygdala (r = .29, p <. 
05) and right amygdala (r = .31, p <.05) volume. No correlations were observed between age at 
disease onset or disease duration with regional or total brain volume. 
6.3 Structure-Function Relationships  
6.3.1. Total and Lateralized Regional Brain Volumes and Cognitive Outcomes 
Hippocampal, amygdala, and thalamic volumes were not significantly associated with 
accuracy on Word Memory collapsing across groups (Table 13), though trends were observed 
with the total (r = .21, p = .05) and left thalamus (r = .23, p = .03). In contrast, higher total (r = 
.32, p = .003) and left thalamic volume (r = .34, p = .001) was associated with faster response 
time on Emotion Recognition collapsing across groups. Trends were also noted between the right 
thalamus (r = .27, p = .01), total hippocampus (r = .22, p = .05), and the left hippocampus (r = 
.23, p = .03) with faster response time on Emotion Recognition collapsing across groups (Table 
13). The relationship between total thalamus and Emotion Recognition are presented by group in 
Figures 12 and 13. 
Finally, given the near significant association between the hippocampus and faster 
response time on Emotion Recognition (p = .03), we used multiple linear regression to examine 
whether total hippocampal volume accounts for additional variance in response time on Emotion 
Recognition after controlling for accuracy on this task, as well as total volume of the thalamus 
and brain (Table 14). This multiple linear regression predicting response time on the Emotion 
Recognition test revealed that hippocampal volume (β = 0.06, 95% CI [-0.39, 0.50], p = .80) did 
not account for any additional variance in the model after controlling for accuracy (β = -0.21, 
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95% CI [-0.53, 0.11], p = .19), volume of the total thalamus (β = 0.19, 95% CI [0.02, 0.35], p = 
.03), and total brain volume (β = -0.002, 95% CI [-0.01, 0.003], p = .41). These set of variables 
explained 12% of variance in response time on Emotion Recognition, R2 = 0.12, F(4,83) = 2.89, 
p = .03.  
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Table 13 
Correlations (two-tailed) Between MRI and Z-score Accuracy on Word Memory and Z-score 
Response time on Emotion Recognition for MS and HCs ≥ 15 Years at Scan 
 
 
Outcome 
 
N 
 
 
MRI Metric 
 
Pearson r Correlations 
 
 Total Left Right 
Word Memory  
Accuracya 
87 
46 
42 
    
  Hippocampus .11 
.04 
.04 
.08 
-.02 
-.02 
.14 
.10 
-.05 
   
Amygdala 
 
.09 
.11 
-.16 
 
.10 
.12 
-.14 
 
.08 
.09 
-.16 
   
Thalamus 
 
.21 
.06 
.13 
 
.22 
.07 
.14 
 
.19 
.05 
.10 
   
Total brain 
 
.19 
.20 
.02 
 
- 
- 
- 
 
- 
- 
- 
Emotion Recognition  
Response Timea  
88 
46 
42 
    
  Hippocampus .23* 
.18 
.13 
.23* 
.19 
.11 
.22 
.16 
.14 
   
Amygdala 
 
.20 
.15 
.16 
 
.20 
.16 
.15 
 
.19 
.12 
.15 
   
Thalamus 
 
.32*** 
.26 
.09 
 
.34*** 
.24 
.21 
 
.27* 
.25 
-.05 
   
Total brain 
 
 
.12 
-.01 
-.10 
 
  - 
  - 
  - 
 
  - 
  - 
  - 
All participants (n = 88), MS patients (n = 46), Healthy Controls (n = 42) 
a Partial correlations controlling for response time 
Note: Sample size differs across tests because data were missing or deemed invalid for some 
patients.  
* p <.05; ** p <.01; *** p <.005
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Figure 12. Scatterplot of Emotion Recognition Response Time       Figure 13. Scatterplot of Emotion Recognition Accuracy  
Z-score with Total Thalamic Volume by Group.       Z-score with Total Thalamic Volume by Group. 
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Table 14 
Multiple Linear Regression Predicting Response Time on the Emotion Recognition Test from 
Accuracy, and MRI Volumetrics of the Total Hippocampus, Thalamus, and Brain Volume 
 
Model B (cm3) SE p 95% Confidence  
Interval for Mean 
Lower        Upper 
R2 
Emotion Recognition 
(Response Time) 
              
     Intercept   .03            0.12 
     Accuracy -0.21 0.16 .19 -0.53          0.11  
     Total Hippocampus 0.06 0.22 .80 -0.39           0.50  
     Total Thalamus 0.19 0.08 .03 0.02           0.35  
     Total Brain Volume -0.002 0.002 .41 -0.01           0.003  
Note: MRI values were rescaled to cm3 (from mm3) to yield interpretable unstandardized Beta 
coefficients.  
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7.0 Discussion 
The purpose of this research was to clarify the association between episodic memory and 
social cognition (i.e., identification of emotional expression) using relevant subtests from the 
PCNB. We also investigated whether patients with pediatric-onset MS differed from healthy 
controls on 1) accuracy and response time on these tasks and 2) the volume of brain structures 
thought to be affiliated with these functions. Broadly, the results provide evidence of a 
relationship between memory and identification of emotional expression. The findings also 
suggest that patients have smaller total and regional brain volume (i.e., hippocampus, amygdala, 
and thalamus). Despite the reduction in total and regional brain volumes in the MS group, only 
the thalamus was associated with response time on the Emotion Recognition task. The following 
sections will consider patient characteristics, overall findings and interpretation of the findings in 
the context of the current literature, and limitations of the present study as well as future 
directions. 
7.1 Findings from the Present Study 
7.1.1 Sample Characteristics 
 Our patient group was similar to some previous pediatric-onset MS samples in terms of 
the female-to-male ratio, disease duration, presence of fatigue, and level of disability (Till et al. 
2011; Fuentes et al. 2012; Green et al. 2018). Also comparable to these samples, our patients did 
not differ on a self-report questionnaire assessing symptoms of anxiety and depression. 
Additionally, patients and controls did not differ from each other with respect to sex, level of 
education, and socioeconomic status as measured by years of parental education. Hence, the 
conclusions of the current study are felt to be generalizable in the context of pediatric-onset MS. 
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7.1.2 Cognitive Outcomes 
 The first aim of this research was to assess whether there is an association between 
memory and identification of emotional expression. Accuracy on the Face Memory subtest was 
positively correlated with performance on the Emotion Recognition and Emotion Differentiation 
tasks collapsing across groups. It may be that accuracy on the Face Memory subtest 
demonstrated the strongest correlation with accuracy on the emotion tasks (versus Object and 
Word Memory with the emotion tasks) given the common face processing aspect. In addition to 
this finding and in line with our hypothesis, slower response time across all tasks was also 
positively associated with response time on the aforementioned social cognition tasks collapsing 
across groups. This is a novel finding given that no studies to our knowledge have directly 
examined the correlation between memory and facial emotion identification abilities in patients 
with pediatric-onset MS. Though a similar recent study by our lab (Green et al. 2018), from 
which we based the present research, showed independent relationships for patients (but not 
HCs) between Memory for Stories and Abstract Visual Memory on the TOMAL-2 (Reynolds & 
Voress, 2007) with Functional Communication on the Behaviour Assessment System for 
Children, 2nd Edition: Parent Rating Scale (BASC-2 PRS; Reynolds & Kamphaus, 2004). Green 
and colleagues (2018) also found significant associations between reduced amygdala volume 
with Abstract Visual Memory, Functional Communication, and Social Skills (also measured by 
the BASC-2). Again, these relationships were only evident for patients.  
In our study, we also examined whether the performance of pediatric-onset MS patients 
differed from healthy controls on episodic memory and identification of emotional expression 
tasks. In line with previous research (MacAllister et al. 2005; Amato et al. 2008; Till et al. 2013), 
our study identified that patients with pediatric-onset MS experience greater challenges with 
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verbal memory versus visual memory. Specifically, our patient group performed significantly 
less accurately than controls on Word Memory after controlling for response time. No significant 
differences were observed between groups on the visual memory tasks (i.e., Face and Object 
Memory), although the mean scores of the patients were lower than the mean scores of the HCs 
on both visual memory subtests.  
Prior studies have reported a deficit in remembering word lists in individuals with 
pediatric-onset MS, although researchers of these studies used immediate and delayed recall 
tasks (Amato et al. 2008; Till et al. 2013; MacAllister et al. 2005; Fuentes et al. 2012; 
MacAllister et al. 2007; Smerbeck et al. 2011). In contrast to the methodology employed in 
previous research, we used an immediate recognition word task and observed deficits which may 
suggest a deficit at the encoding stage for verbal information. However, deficiency with word 
recall cannot be ruled out as this was not assessed.  
Interestingly, we also observed that patients with pediatric-onset MS were better able to 
recognize emotional states from facial expressions (on the Emotion Recognition subtest) than 
HCs after controlling for accuracy, however, they needed significantly more time to do so (p = 
.009). Patients did not differ from controls on accuracy or response time when asked to identify 
which of two faces was showing a particular emotion to a greater extreme (i.e., Emotion 
Differentiation). Social cognition has only been examined in a few studies of adults with MS 
(Pinto et al. 2012; see meta-analysis by Cotter et al. 2016; Henry et al. 2017) and one group of 
patients with pediatric-onset MS (Charvet et al. 2014). Charvet and colleagues used higher-level 
ToM tasks which require inferential and deductive reasoning. The Emotion Recognition task 
administered in our research is easier in comparison to that employed by the other researchers. 
Although the Emotion Recognition test we used has an open-ended response format that permits 
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participants to adjust their response speed for improved accuracy, this is the only subtest 
included in our analyses where the instructions state that participants should respond as quickly 
and as accurately as possible. As such, a speed-accuracy trade-off is hypothesized whereby HCs 
were less accurate on this task as they decreased their response latency and MS patients were 
more accurate and significantly slower. Alternately, the discrepancy between results when 
looking at accuracy and response time on the Emotion Recognition test may suggest that 
response time is more sensitive to MS pathology than accuracy.  
Overall, the episodic memory and social cognitive performance of MS patients across all 
subtests examined on the PCNB fell within the average range. Relative to healthy controls, 
however, we observed lower mean scores among patients on all tests for both accuracy and 
response time (with the exception of accuracy on Emotion Recognition where patients 
outperformed controls). The groups differed significantly on Word Memory (accuracy) and 
Emotion Recognition (response time). Despite small effect sizes at the group level, our findings 
do have clinical relevance at the individual level. A higher proportion (although not statistically 
significant) of patients in the MS group (relative to HCs) showed impaired performance on most 
tasks (excluding accuracy on Emotion Recognition (again highlighting a compromise between 
speed and accuracy on this test) and the Motor Praxis test) for both accuracy and response time. 
Functional implications of our findings are discussed further below.   
There were no significant associations between clinical characteristics of the MS group 
and performance on tasks that were identified as being significantly poorer in the MS group 
relative to HCs. Earlier identification and diagnosis of the disease in recent years, access to 
quality care at specialized clinics, and improvements in disease modifying therapies may explain, 
at least in part, why most patients are not impaired. Furthermore, the majority (73.6%) of our 
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sample was recruited from urban, Canadian pediatric health-care centres where several medical 
services are covered by provincial health care plans. At this time, there is insufficient evidence to 
suggest that the plasticity of the young brain can compensate for the impact of disease in this 
population (Till et al., 2011; Charvet et al., 2014; Ghezzi et al., 2017). There is some indication 
that plasticity may occur early in the disease for some individuals, but then reach a threshold 
where the compensatory networks cannot meet demands and impairment manifests. Thus, 
longitudinal research is needed to examine the trajectory of episodic memory and social 
cognitive performance as time from disease onset increases. On average, our patients were 
relatively early in their disease course (M = 3.61 years).  
7.1.3 MRI Outcomes 
A third goal of this research was to assess whether patients with pediatric-onset MS have 
smaller hippocampal, amygdala, and thalamic volume in comparison to healthy controls. We 
also examined normalized total brain, grey matter, and white matter volumes. 
Consistent with previous imaging research in this population (Mesaros et al., 2008; Till et 
al., 2011; Kerbrat et al., 2012; Green et al., 2018; Fuentes et al., 2012), normalized total brain 
and thalamic volumes differed significantly between the two groups, with the MS group 
displaying smaller volumes compared to HCs. As previously mentioned, MRI studies in 
pediatric-onset MS have yielded mixed findings regarding volume of limbic structures. Our 
research is aligned with Rocca and colleagues (2016) in that we also found that patients have 
smaller hippocampal volumes and Fuentes and colleagues (2012) in that we also noted that 
patients had smaller amygdala volumes than HCs. Importantly, the effect size was 
disproportionately larger for the thalamus compared with the amygdala and hippocampus 
suggesting (and in line with previous studies) that the thalamus is particularly susceptible to the 
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disease with relative sparing of the other structures we examined. Longitudinal studies are 
needed to determine whether the reduction in brain volume for patients indicates atrophy or 
reflects lack of age-expected brain development.  
7.1.4 Structure-Function Relationships 
 Brain-behaviour relationships were only examined for tasks that demonstrated significant 
between group differences. Contrary to our hypothesis, the hippocampus and amygdala 
independently did not show any significant associations with accuracy on the Word Memory test 
or response time on the Emotion Recognition test. The thalamus was most robustly associated 
with response time on the Emotion Recognition task. A near-significant association (p = .03) was 
observed between the hippocampus and response time on the Emotion Recognition task. Based 
on correlations alone, it is hard to disentangle whether the hippocampus is actually related to 
performance on this task or if the thalamus (due to its diffuse connectivity with structures of the 
limbic system and entire cerebral cortex) is actually driving the relationship (Mesaros et al., 
2008; Hwang, et al., 2017). Therefore, we examined whether total hippocampal volume accounts 
for any additional variance after controlling for accuracy on the Emotion Recognition task, total 
thalamic volume, and total brain volume. This multiple linear regression predicting response 
time on the Emotion Recognition task revealed that total thalamic volume (β = 0.19, p = .03) was 
a significant predictor, whereas volume of the total hippocampus (β = 0.06, p = .80) did not 
account for any additional variance in the model, R2 = 0.12, p = .03. 
7.2 Methodological Considerations 
The present research acts as a starting point to describe aspects of cognition that have not 
been explored in-depth or at all (i.e., identification of emotional expression) in young people 
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with MS. Our study goes beyond commenting on significant relationships and describes the 
pattern of findings which suggest that overall, patients with MS demonstrate challenges with 
aspects of both episodic memory and social cognition, with the greatest difficulties observed in 
Word Memory and Emotion Recognition tasks.  
Currently, the Symbol Digit Modalities Test (SDMT) is the gold standard screening 
measure for cognitive impairment in pediatric-onset MS due to its quick administration and high 
sensitivity (Charvet et al., 2014). However, it can be argued that the PCNB may be a tool with 
greater specificity. When deciding whether to use the SDMT or PCNB, one must consider 
clinical feasibility as the PCNB requires approximately one-hour to complete in the presence of a 
trained assessor, versus the 90-second SDMT which can be administered by a neurologist during 
a medical appointment. An advantage of the PCNB over the SDMT is the evaluation of multiple 
domains of functioning versus one domain which may or may not capture challenges that the 
patient is experiencing. The PCNB also has the capacity for separate measurement of speed and 
accuracy of performance, unlike the SDMT and many other commonly used neuropsychological 
assessment tools. Considering both when assessing patients with pediatric-onset MS is 
important, as our results suggest that patients have specific deficits in response time that exist 
independently of accuracy and vice-versa. For example, if a patient is found to perform within 
normal limits on the Affect Recognition subtest of A Developmental Neuropsychological 
Assessment, 2nd edition (NEPSY-II; Korkman, Kirk, & Kemp, 2007), based on our findings, we 
cannot conclude that they do not have challenges with identification of emotional expression. 
Creating tests for future versions of neuropsychological assessment tools that assess both 
accuracy and response time would be optimal, similar to the utility of a d-prime score for task 
performance which takes into account the hit rate (i.e., proportion of trials where a participant 
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responds to a stimulus) and false alarm rate (i.e., proportion of trials where a participant responds 
when the stimulus is not present). Assessment measures that provide a score that considers both 
accuracy and response time on a given task may be helpful in evaluating a speed-accuracy trade-
off and results are likely to also be more generalizable to performance in the real-world.  
Experimenters have long been interested in understanding the relationship between speed 
and accuracy. Although researchers have developed methods that consider these two important 
metrics simultaneously, many cognitive psychology studies still use either response time or 
accuracy (the latter is primarily used in memory research) as the primary outcome (Voss et al., 
2013). Some researchers have used binning, whereby data is organized into “bins” by response 
time. Other researchers use the inverse efficiency score (IES; Townsend & Ashby, 1983) which 
is a proportion of response time to errors. The IES has been used in emotion recognition research 
(e.g., Rossignol et al., 2009) and according to the researchers, provided more meaningful data 
than response time alone. We suggest that an overall performance measure will be helpful in 
examining the influence of latency on accuracy in pediatric-onset MS, versus examining the 
independent outcomes for these constructs (Heitz, 2014; Hughes et al., 2014).  
Despite its strengths, we are not advocating that the PCNB replace the use of traditional 
individualized neuropsychological assessment for patients reporting cognitive and/or academic 
challenges. This point cannot be minimized, particularly given the limitation of the memory tests 
that do not assess immediate or delayed recall of visual or verbal information which may be the 
most at-risk memory functions in MS (MacAllister et al., 2005; Amato et al., 2008; Amato et al., 
2010). Rather, the PCNB likely has the most value as a screener to identify aspects of cognition 
that may be problematic at the individual-level, which can then be followed-up with traditional 
neuropsychological assessments for those particular domains. Despite the sensitivity of the 
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Motor Praxis test (i.e., ability of the test to successfully differentiate patients and HCs), we also 
suggest that the PCNB be supplemented by higher-level visuomotor integration tasks (e.g., 
Beery-Buktenica Developmental Test of Visual-Motor Integration 6th edition; Beery et al., 2010) 
and physical tasks of fine motor dexterity (e.g., 9-Hole Peg Test; Mathiowetz et al., 1985). 
Performance on these tasks have been shown to be impacted early on in pediatric-onset MS 
(Julian et al., 2013). Moreover, dual-tasks that simultaneously assess executive-control/motor 
planning and fine-motor function has utility in better understanding motor speed-accuracy trade-
offs which in-turn may better reflect day-to-day functioning in this domain.  
7.3 Relevance 
At present, there is no cure for MS. It is therefore necessary to strive to continue to 
understand the cognitive and psychosocial sequelae of the disease. Reduced processing speed is a 
common consequence of pediatric-onset MS although the role of reduced processing speed in 
memory function and social cognition had not been explored until this study to our knowledge. 
Our results provide important big picture insights into challenges that may be faced by children 
and youth in relation to episodic memory and identification of emotional expression. We believe 
that this is the first study to examine the latter in young people with MS.  
We identified that patients with pediatric-onset MS do experience challenges with aspects 
of episodic memory and identification of emotional expression that may have clinically relevant 
implications. In particular, slowed identification of emotional expression may be problematic in 
social interactions. Prompt and accurate emotion identification is vital for successful social 
interactions and relationships as faces provide us with information about what others may be 
thinking or feeling (Charvet et al., 2014). Studies that have demonstrated deficits in identification 
of emotional expression in adult MS note that it is associated with reduced psychosocial quality 
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of life (Phillips et al., 2011; Cotter et al., 2016; Bora, Özakbaş, Velakoulis & Walterfang, 2016). 
In children with MS, challenges which emotion recognition may also lead to restricted 
opportunities for socialization and diminished quality of life (Charvet et al., 2014; Cotter et al., 
2016; Bora et al., 2016). This is particularly concerning in a pediatric population given the 
heightened importance of socialization in adolescence, the developmental transition between 
childhood and adulthood (Smetana et al., 2015). 
In addition, social cognitive dysfunction may combine with other consequences of MS 
that were not examined in this particular study (e.g., fatigue and frequent medically-related 
absences from school) to further disrupt social interactions and/or willingness to engage in 
relationships (Green et al., 2018). This may exacerbate feelings of sadness and insecurity that 
have been endorsed by pediatric MS patients in previous work (Till et al., 2012). Understanding 
memory and social cognitive challenges in this population is important so that targeted 
interventions and recommendations can be developed to support patients with MS.  
7.4 Limitations and Future Directions 
Our research is limited by its cross-sectional, correlational design. Longitudinal studies 
have the capacity to examine trajectories of cognitive challenges and causality (i.e., does 
neuropathology caused by the disease lead to cognitive impairment). This could not be 
accomplished with our design. Future studies in pediatric-onset MS are needed to explore 
whether brain volumes continue to decrease over time and if this can account for the documented 
decline in cognitive capacity with longer disease duration (Amato et al., 2010; Till et al., 2013).  
Additionally, there is a potential concern regarding scaling with SIENAx in a developing 
cohort given that the images are registered to an adult template. Despite concerns, this approach 
has been used in previously published cross-sectional work (Kerbrat et al., 2012; Fuentes et al., 
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2012). Therefore, by using SIENAx we are able to place our findings obtained from volumetric 
analyses in the context of these prior results. We excluded participants less than 15 years of age 
from our MRI analyses to avoid as much as possible the confound of brain growth.  
Another limitation of this study is that proper comparison to individuals of the same age 
was not feasible. Z-scores were created based on our sample of HCs and age effects were 
accounted for by the use of three sets of norms (i.e., 8-13 years, 14-17 years and >18 years). This 
method was deemed more appropriate than comparison to the American PCNB normative 
sample, given significant differences in parental education (a proxy for socioeconomic status) 
between our participants and the normative sample. A final limitation is in the uniform use of 
pediatric versions of the PCNB tasks despite our recruitment of participants over the age of 18. 
This may have led to ceiling effects (most evident for both patients and controls on Word 
Memory) for older individuals. An adult version of the PCNB is available and may be more 
appropriate for use in clinical settings.  
Finally, while we considered the impact of total and lateralized volumes of the entire 
hippocampus and amygdala, this study did not assess the numerous and heterogeneous subfields 
and nuclei of these brain structures that have to been shown to have different functions for 
specific aspects of emotion processing and memory (e.g., the lateral nucleus of the amygdala 
participates in encoding and storage of affective memory) (Mueller et al., 2011; Erlich et al., 
2012). As well, previous pathological studies in adult MS have seen differential impact of the 
disease on hippocampal subfields with relative sparing of CA4 and the subiculum 
(Papadopoulos, 2009). Future studies should segment the hippocampus and amygdala and also 
utilize functional imaging modalities (e.g., electroencephalography, functional magnetic 
resonance imaging) in order to visualize brain activity and see if there are differences in the 
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recruitment of networks between patients with pediatric-onset MS and HCs when completing 
subtests from the PCNB.  
7.5 Conclusions 
We explored the relationship between performance on tests of episodic memory and 
identification of emotional expression using the PCNB in a sample of patients with pediatric-
onset MS and HCs. Qualitative brain volumetric measures were used to elucidate the relationship 
between neuropathology and cognitive performance. In summary, our findings revealed that 
accuracy on the Face Memory subtest was correlated with performance on all social cognition 
tasks collapsing across groups. Slower response time across all episodic memory tasks was 
associated with slower response time on all social cognition tasks collapsing across groups. Our 
sample of pediatric-onset MS patients demonstrated lower accuracy on the Word Memory task, 
slower response time on the Emotion Recognition task, and significantly reduced volume of the 
hippocampus, amygdala, and thalamus as well as total brain volume relative to HCs. Despite 
group differences in total and regional brain volume, only thalamic volume appeared to show a 
moderate positive association with response time on the Emotion Recognition test.  
The PCNB has been used in previous studies to detect cognitive impairment in youth 
with psychotic symptoms, mood disorders, herpes simplex virus, type 1, and the hepatitis C virus 
(Gur et al., 2014; Merikangas et al., 2017; Thomas et al., 2013; Ibrahim et al., 2016). Our data 
validates that the PCNB is also sensitive to episodic memory and social cognitive impairment in 
pediatric-onset MS as it was able to successfully differentiate the performance of patients and 
HCs. Further understanding of the temporal progression for atrophy of the hippocampus, 
amygdala, and thalamus, as well as their consequences for memory and social cognitive 
dysfunction in pediatric-onset MS, necessitates longitudinal investigation. 
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9.0 APPENDIX. Supplemental Tables 
Supplemental Table 1 
PCNB Subtests in Order of Appearance 
Note. Subtests in bold are the primary outcomes used in the current study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subtest Domain 
Motor Praxis Test  Sensorimotor 
Measured Emotion Differentiation Test Social Cognition 
Penn Verbal Reasoning Test Complex Cognition 
Face Memory Test Episodic Memory 
Emotion Recognition Test Social Cognition 
Letter N-Back  Executive Function 
Word Memory Test Episodic Memory 
Age Differentiation Test Social Cognition 
Variable Penn Line Orientation Test  Complex Cognition 
Visual Object Learning Test Episodic Memory 
Penn Matrix Analysis Test  Complex Cognition 
Penn Continuous Performance Test Executive Function 
Penn Conditional Exclusion Test Executive Function/Complex Cognition 
Go-No-Go Test Executive Function 
Computerized Finger-Tapping Task Sensorimotor 
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Supplemental Table 2 
Scanner Utilized at Each Site in the CPDDS 
Note. Site in Newfoundland (Janeway Children’s Health and Rehabilitation Centre) does  
not have a 3T scanner. No scans for the present study were acquired at Trillium Health Partners.  
 
 
Supplemental Table 3 
Sensitivity Analysis: Participants Impaired on Age Differentiation (Z-score Accuracy) Excluded 
 
Domain Task MS Group 
M(SE) 
HC Group 
M(SE) 
 
p 
Social Cognitiona,b Age Differentiationa - - -  
  
Emotion Recognitiona,b 
 
0.33 (0.10) 
 
 
0.07 (0.09) 
 
.06 
 Emotion Differentiationa -0.12 (0.11) 0.11 (0.09) .12 
Abbreviations: MS = multiple sclerosis; HC = healthy control 
Note. p-values (ANCOVA) represent group differences after controlling for response timea and 
sexb (where indicated); Classification of impairment was based on a score falling 1.5 standard 
deviations below the mean; Sample size differs across tests because data were missing or deemed 
invalid for some patients.  
 
 
 
 
 
 
Site Scanner(s) 
Alberta Children’s Hospital GE - 750W - 3.0T 
 
Children's Hospital at London Health Sciences 
Centre 
 
Siemens –PRISMA Fit – 3.0T 
 
Children's Hospital of Philadelphia 
 
Siemens – Verio – 3.0T 
 
Hospital for Sick Children  
 
Siemens – Tim Trio – 3.0T 
Siemens – PRISMA Fit – 3.0T 
 
Janeway Children's Health and Rehabilitation 
Centre 
 
N/A 
 
Montreal Children's Hospital  
 
Siemens – TimTrio– 3.0T 
Siemens – PRISMA Fit 3.0T 
 
The Children's Hospital of Manitoba 
 
Siemens – Verio – 3.0T 
 
Trillium Health Partners 
 
N/A 
